Focused on oncology, WILEX develops diagnostic and therapeutic product
candidates based on antibodies, which are available for
out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract
research services and an antibody drug conjugate (ADC)
14.04.2015: WILEX publishes Half-yearly Financial ReportWILEX AG today published its financial report on the first six months of 2015.
The focus in these first half-year was on the research activities of its subsidiary Heidelberg Pharma GmbH and the funding of WILEX AG.
Seite gelesen: 326887 | Heute: 138